- 05 November
-
Medsintez Plant participated in a key industry event, Product Innovation Fair in Medicine and Healthcare, which took place in Moscow on October 29–30. Viktor Fisenko, First Deputy Minister of Healthcare of Russia, attended the exhibition of domestic innovations in the field of drugs and medical products.
- 25 October
-
The 3d Scientific and Practical Conference The Ural Peaks. Respiratory Infections 2025 was held in Ekaterinburg on October 15–16 as part of the 4th International Forum Days of Virology 2025. The event organized by the Ministry of Health of the Sverdlovsk Region, the Smorodintsev Research Institute of Influenza, and the Ural State Medical University brought together over 1,100 participants in person and online from 36 cities across Russia.
- 24 October
-
In September 2025, the Russian Ministry of Health issued a registration certificate for a new dosage form of the broad-spectrum antiviral drug TRIAZAVIRIN® for the treatment of ARVI in school-age children—100 mg.
- 20 October
-
On October 10, 2025, a representative delegation visited the Medsintez Plant. Among the visitors, there were members of the State Duma of the Russian Federation, representatives of the Government and Legislative Assembly of the Sverdlovsk Region, the head of the Novouralsk Urban District, and leading regional experts in the field of medical science. The main purpose of the visit was to assess the enterprise's success in import-substituting drug production, become familiar with its brand-new products, and discuss development options of the pharmaceutical industry in the region.
- Home
- Cluster members
- As & Co Pharm group LLC
As & Co Pharm group LLC
The enterprise As & Co Pharm group LLC is the Ural pharmaceutical company Asco Pharm. The company is a portfolio project of the Ural Federal University (UrFU) Innovation Development Fund, UrFU Innovation Infrastructure and INNOPORT startup studio. Asco Pharm has been researching and developing medicines and dietary supplements for over 15 years. The flagship project of the company is the development of an innovative original drug for the prevention and treatment of osteoporosis, which is in the process of going through the necessary clinical and bureaucratic procedures. In this regard, in order to accelerate the commercialization of the project, the company, based on this drug, brought to the market an innovative dietary supplement REOCYTAN Calcium- Magnesium-D3. Even during the research period, the project showed excellent results, opening up a completely new approach in the fight against osteoporosis and calcium deficiency. The drug uses a patented formula that has no analogues in the world and an innovative technology for delivering calcium to bone tissue. The project has received great interest from the scientific community in Russia and abroad. With this project, the company won the largest business accelerator in the Urals of the Ural Federal University in 2018 And in 2020, Reocytan won the prestigious medical innovation competition held by TIPA in South Korea. Asco Pharm's portfolio also includes more than 20 developments at various stages: recovery after strokes and severe brain injuries, tissue repair after injuries or severe pathologies (heart failure, AECB, SARS, COVID, etc.) oncoprophylaxis technology, technology for removal of hepatitis B virus complicated by D, technology for preventing an autoimmune response in pneumonia of various etiologies, a line of products that suppress muscular dystrophy, etc.
The company is planning to bring several more brands to the market in the next few years.
Tel.: +7 (922)-115-30-63
E-mail: info@ascopharm.ru
www.ascopharm.ru
www.reocytan-calcium.com
